RABEPRAZOLE SODIUM + RABEPRAZOLE SODIUM
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Non-erosive Gastroesophageal Reflux Disease
Conditions
Non-erosive Gastroesophageal Reflux Disease
Trial Timeline
May 1, 2005 → Oct 1, 2005
NCT ID
NCT00165672About RABEPRAZOLE SODIUM + RABEPRAZOLE SODIUM
RABEPRAZOLE SODIUM + RABEPRAZOLE SODIUM is a phase 3 stage product being developed by Eisai for Non-erosive Gastroesophageal Reflux Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00165672. Target conditions include Non-erosive Gastroesophageal Reflux Disease.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00165672 | Phase 3 | Completed |
Competing Products
6 competing products in Non-erosive Gastroesophageal Reflux Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| YH1885L(Revaprazan) + Esomeprazole 20mg + placebo | Yuhan | Phase 2 | 52 |
| E3810 + E3810 + Placebo | Eisai | Phase 3 | 77 |
| Omeprazole | AstraZeneca | Phase 3 | 77 |
| Omeprazole | AstraZeneca | Phase 3 | 77 |
| Vonoprazan + Placebo | Phathom Pharmaceuticals | Phase 2 | 47 |
| Vonoprazan + Placebo | Phathom Pharmaceuticals | Phase 3 | 72 |